Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 4Advanced Solid Tumors 4Solid Tumor 3Mesothelioma 3Advanced Solid Tumor 3Advanced Solid Tumours 2Thymoma 1Neuroendocrine Tumors 1Mesothelioma, Malignant 1Malignant Solid Tumors 1Lung Neoplasms 1Advanced Solid Tumor, Adult 1Advanced Cancer 1

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1asciminib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Solid Tumors × olaparib × Other solid neoplasm × Clear all
NCT00516438 2010-12-08

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan

AstraZeneca

Phase 1 Completed
48 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡